Embedded Files
DelveInsight's comprehensive "Obesity Pipeline Insight 2025" analysis delivers detailed information on more than 80 organizations and over 100 investigational medications within the obesity therapeutic development landscape. The analysis encompasses drug candidate profiles across both clinical and preclinical phases, along with therapeutic evaluations categorized by product classification, developmental phase, delivery method, and molecular structure. The report also identifies discontinued or dormant obesity drug development programs.
Access comprehensive insights on Obesity Pipeline therapies and emerging treatment landscapes @ Obesity Pipeline Report
Major Highlights from the Pipeline Analysis
As of December 01, 2025, Boehringer Ingelheim launched an investigation enrolling adults aged 18 years and above with a body mass index (BMI) of 27 kg/m² or higher. Eligible candidates include those diagnosed with cardiovascular conditions or chronic kidney disease, or individuals presenting with two or more weight-related health complications or cardiovascular risk factors. All participants must have previously attempted weight reduction through dietary modifications.
On November 28, 2025, NodThera Limited revealed plans for a Phase 2a investigation examining NT-0796's safety profile and effectiveness when combined with semaglutide in obese patients throughout a 6-month therapeutic period.
On November 25, 2025, Novo Nordisk A/S commenced an investigation evaluating how the investigational medication NNC0519-0130 facilitates weight reduction in individuals with elevated body weight. The investigation will assess up to 6 dosage levels of NNC0519-0130. Subjects will receive 1-2 weekly injections administered subcutaneously via thin needle in the abdominal region, thigh area, or upper arm. Total investigation duration spans approximately 42 weeks.
The pipeline landscape features over 80 active organizations advancing more than 100 therapeutic candidates for obesity management.
Key Organizations in Obesity Drug Development
Leading entities include Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, among others.
Notable Investigational Treatments
Promising candidates include APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and additional compounds.
Explore detailed analysis of Obesity Clinical Trials and emerging therapeutic developments @ Obesity Clinical Trials and Studies
The analysis delivers disease background information, pipeline landscape overview, and therapeutic evaluation of primary pipeline candidates within this therapeutic area. It emphasizes gaps in current treatment options for obesity management.
Understanding Obesity
Obesity represents the disproportionate or abnormal accumulation of adipose tissue within the body that compromises health through its connection with increased risk for developing diabetes mellitus, cardiovascular conditions, hypertension, and hyperlipidemia. It constitutes a major public health challenge that has continuously intensified throughout the last five decades.
Emerging Therapeutic Candidates
Survodutide: Zealand Pharma
Survodutide (BI 456906) represents a long-acting dual receptor agonist targeting both glucagon and GLP-1 receptors, formulated for once-weekly subcutaneous delivery. This medication activates two critical gut hormone receptors concurrently and potentially provides superior effectiveness compared to existing single-hormone receptor agonist therapies. Survodutide targets obesity treatment and nonalcoholic steatohepatitis (NASH). Boehringer Ingelheim is progressing survodutide through three international Phase III investigations in individuals experiencing overweight or obesity.
Ecnoglutide: Sciwind Biosciences
Glucagon-like peptide-1 (GLP-1) analogues represent effective therapeutic options for managing type 2 diabetes and obesity, demonstrating clinical promise for NASH treatment. Ecnoglutide (XW003) constitutes a novel, cAMP signaling biased, long-acting GLP-1 analogue engineered for enhanced biological performance, economical production, and weekly administration. Presently, this medication is undergoing Phase III clinical investigation for obesity treatment.
CT-868: Carmot Therapeutics
CT-868 functions as a dual receptor modulator targeting both GLP-1 and GIP receptors, featuring a distinctive pharmacological profile engineered for enhanced tolerability at the GLP-1 receptor. The synergistic action of GLP-1 and GIP produces superior body weight reduction and glucose regulation. CT-868 requires daily dosing to optimize effectiveness and tolerability. This dual agonist candidate emerged through chemotype evolution technology as a peptide-small molecule hybrid structure capable of mimicking the endogenous GLP-1 hormone. Phase I trial data revealed compelling pharmacodynamic activity across multiple clinical parameters in overweight and obese healthy subjects, with a safe and generally well-tolerated profile. Carmot Therapeutics is expanding these findings in overweight and obese patients with type 2 diabetes to validate CT-868's impact on glycemic regulation, weight reduction, and tolerability. Currently, the medication is in Phase II development for obesity treatment.
DD01: D&D Pharmatech
DD01 represents a proprietary, imbalanced dual agonist targeting both GLP-1 and glucagon receptors, exhibiting an 11-day half-life in non-human primates. DD01 is being advanced as a potentially disease-modifying therapeutic for obesity and hepatic steatosis. DD01 administration produced weight reduction, decreased hepatic fat content, and enhanced glucose tolerance in preclinical obesity, diabetes, and fatty liver models. In preclinical models of diabetes and nonalcoholic fatty liver disease (NAFLD), DD01 demonstrated capability to reduce weight and blood glucose while improving insulin sensitivity and lipid metabolism, potentially ameliorating NASH. DD01 showed superior effectiveness in preclinical models versus semaglutide, an approved GLP-1R receptor agonist; mechanistically, DD01's effects persisted following treatment discontinuation. It is currently undergoing Phase I clinical evaluation to examine the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously (SC) administered DD01 in overweight/obese subjects with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD).
Discover insights into Obesity Unmet Needs and future treatment opportunities @ Obesity Unmet Needs
Report Features
The pipeline analysis delivers comprehensive insights regarding organizations developing obesity therapeutics, including aggregated therapy counts per organization.
It evaluates various therapeutic candidates classified into early-phase, mid-phase, and late-phase development for obesity management.
Organizations are engaged in targeted therapeutic development with corresponding active and inactive (dormant or discontinued) initiatives.
Investigational medications are analyzed based on developmental phase, delivery route, target receptor, monotherapy versus combination therapy, mechanism of action, and molecular classification.
Comprehensive analysis of partnerships (organization-organization and organization-academia collaborations), licensing arrangements, and funding details for future market advancement.
Product Classification by Delivery Route
Products are organized under various delivery routes including:
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Product Classification by Molecular Structure
Products are categorized under various molecular types including:
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Gain strategic intelligence on Obesity Market Drivers, Barriers, and future therapeutic landscape @ Obesity Market Drivers and Barriers, and Future Perspectives
Analysis Scope
Coverage: Global
Featured Organizations: Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others.
Featured Therapies: APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others.
Therapeutic Evaluation by Product Classification: Monotherapy, Combination therapy, Monotherapy/Combination therapy
Therapeutic Evaluation by Development Phase: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Download the complete Obesity Emerging Drugs report to explore key companies and major therapeutic developments @ Obesity Emerging Drugs and Major Companies
Report Structure
Introduction
Executive Summary
Obesity Overview
Obesity Pipeline Therapeutics
Obesity Therapeutic Assessment
Late Stage Products (Phase III)
Survodutide: Zealand Pharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
CT-868: Carmot Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
DD01: D&D Pharmatech
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Obesity Products
Obesity Key Companies
Obesity Key Products
Obesity Unmet Needs
Obesity Market Drivers
Obesity Market Barriers
Obesity Future Perspectives and Conclusion
Obesity Analyst Views
Obesity Key Companies
Appendix
About Us
DelveInsight operates as a premier healthcare-focused market research and consulting organization delivering high-quality market intelligence and analytical insights to support strategic business decisions. Supported by experienced industry specialists and comprehensive knowledge of the life sciences and healthcare industries, the firm delivers customized research solutions and strategic insights to global clients. Engage with the organization to access high-quality, precise, and real-time intelligence for maintaining competitive advantage.
Contact Us
Kanishk
kkumar@delveinsight.com
Page updated
Google Sites
Report abuse